Author:
Li Jie-pin,Liu Yuan-jie,Yin Yi,Li Ruo-nan,Huang Wei,Zou Xi
Abstract
AbstractHepatocellular carcinoma (HCC) is the most widespread histological form of primary liver cancer, and it faces great diagnostic and therapeutic difficulties owing to its tumor diversity. Herein, we aim to establish a unique prognostic molecular subtype (MST) and based on this to find potential therapeutic targets to develop new immunotherapeutic strategies. Using calcium channel molecules expression-based consensus clustering, we screened 371 HCC patients from The Cancer Genome Atlas to screen for possible MSTs. We distinguished core differential gene modules between varying MSTs, and Tumor Immune Dysfunction and Exclusion scores were employed for the reliable assessment of HCC patient immunotherapeutic response rate. Immunohistochemistry and Immunofluorescence staining were used for validation of predicted immunotherapy outcomes and underlying biological mechanisms, respectively. We identified two MSTs with different clinical characteristics and prognoses. Based on the significant differences between the two MSTs, we further identified Follistatin-like 3 (FSTL3) as a potential indicator of immunotherapy resistance and validated this result in our own cohort. Finally, we found that FSTL3 is predominantly expressed in HCC stromal components and that it is a factor in enhancing fibroblast-M2 macrophage signaling crosstalk, the function of which is relevant to the pathogenesis of HCC. The presence of two MSTs associated with the calcium channel phenotype in HCC patients may provide promising directions for overcoming immunotherapy resistance in HCC, and the promotion of FSTL3 expressed in stromal components for HCC hyperfibrosis may be responsible for the poor response rate to immunotherapy in Cluster 2 (C2) patients.
Funder
Youth Science and Technology Project of Suzhou
Natural Science Foundation of China
Jiangsu Province Hospital of Chinese Medicine Peak Academic Talent Project
Advantageous Disciplines Program of Nanjing University of Chinese Medicine
Science and Technology Project of Affiliated Hospital of Nanjing University of Chinese Medicine
State Administration of Chinese Medicine Project
Jiangsu Provincial Science and Technology Department Project
Jiangsu Province Postgraduate Research Innovation Program Project
Publisher
Springer Science and Business Media LLC
Reference94 articles.
1. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. Accessed 15 Mar 2021.
2. Xu, X. F. et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: A multicenter study from China. JAMA Surg. 154(3), 209–217 (2019).
3. Liu, D. & Song, T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. Biosci. Trends 15(3), 142–147 (2021).
4. Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30(16), R921–R925 (2020).
5. Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2021).